July 9, 2020 / 6:24 AM / a month ago

BRIEF-AstraZeneca Says Brilinta Granted USFDA Priority Review For Stroke

July 9 (Reuters) - AstraZeneca PLC:

* ASTRAZENECA PLC - BRILINTA GRANTED US FDA PRIORITY REVIEW FOR STROKE

* ASTRAZENECA - PRESCRIPTION DRUG USER FEE ACT DATE, FDA ACTION DATE FOR THIS SUPPLEMENTAL APPLICATION, IS SCHEDULED FOR Q4 OF 2020.

* ASTRAZENECA- SNDA WAS BASED ON RESULTS FROM PHASE III THALES TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below